|
1
|
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
|
N Engl J Med
|
1996
|
10.69
|
|
2
|
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation.
|
N Engl J Med
|
1991
|
4.17
|
|
3
|
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
|
Ann Oncol
|
2011
|
3.07
|
|
4
|
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.
|
Leukemia
|
2011
|
1.99
|
|
5
|
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
|
Leukemia
|
2006
|
1.83
|
|
6
|
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
|
Leukemia
|
2006
|
1.79
|
|
7
|
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.
|
Ann Oncol
|
2009
|
1.58
|
|
8
|
P53 deletion is not a frequent event in multiple myeloma.
|
Br J Haematol
|
1999
|
1.57
|
|
9
|
Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology.
|
Leuk Res
|
1999
|
1.55
|
|
10
|
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
|
Leukemia
|
2010
|
1.54
|
|
11
|
Minor clone provides a reservoir for relapse in multiple myeloma.
|
Leukemia
|
2012
|
1.54
|
|
12
|
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
|
Leukemia
|
2007
|
1.48
|
|
13
|
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
|
Leukemia
|
2008
|
1.46
|
|
14
|
Interferon alpha-2b therapy in refractory adult chronic thrombocytopenic purpura.
|
Br J Haematol
|
1991
|
1.39
|
|
15
|
Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.
|
Blood
|
1995
|
1.39
|
|
16
|
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres.
|
Br J Haematol
|
2001
|
1.36
|
|
17
|
14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.
|
Cancer Res
|
1999
|
1.23
|
|
18
|
Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.
|
Blood
|
1999
|
1.16
|
|
19
|
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.
|
Br J Haematol
|
1998
|
1.12
|
|
20
|
POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cells.
|
Leukemia
|
1997
|
1.09
|
|
21
|
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
|
Cancer Res
|
1998
|
1.09
|
|
22
|
p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance.
|
Blood
|
2001
|
1.06
|
|
23
|
Multiple myeloma: almost all patients are cytogenetically abnormal.
|
Br J Haematol
|
1996
|
1.05
|
|
24
|
Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients.
|
Arthritis Rheum
|
1993
|
1.02
|
|
25
|
Lenalidomide in the treatment of multiple myeloma: a review.
|
J Clin Pharm Ther
|
2008
|
1.02
|
|
26
|
[POEMS syndrome].
|
Rev Med Interne
|
1997
|
1.02
|
|
27
|
High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization.
|
Genes Chromosomes Cancer
|
1999
|
1.01
|
|
28
|
Role of early splenectomy in malignant lymphomas with prominent splenic involvement (primary lymphomas of the spleen). A study of 59 cases.
|
Cancer
|
1993
|
0.99
|
|
29
|
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
|
Leukemia
|
2013
|
0.99
|
|
30
|
patients with the description of a new scoring system and its validation on 253 other patients.
|
Blood
|
2000
|
0.98
|
|
31
|
Over-expression of the MDM2 gene is found in some cases of haematological malignancies.
|
Br J Haematol
|
1994
|
0.98
|
|
32
|
Rare occurrence of P53 gene mutations in multiple myeloma.
|
Br J Haematol
|
1992
|
0.95
|
|
33
|
Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor.
|
Leukemia
|
2004
|
0.93
|
|
34
|
Acute monocytic leukaemia in adults: treatment and prognosis in 99 cases.
|
Br J Haematol
|
1990
|
0.92
|
|
35
|
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
|
Ann Hematol
|
2010
|
0.92
|
|
36
|
Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma.
|
Leukemia
|
1995
|
0.91
|
|
37
|
Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition.
|
Blood
|
1997
|
0.88
|
|
38
|
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
|
J Clin Pharm Ther
|
2011
|
0.88
|
|
39
|
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.
|
Leukemia
|
2010
|
0.86
|
|
40
|
Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma.
|
Eur J Haematol
|
1996
|
0.85
|
|
41
|
The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases.
|
Leuk Lymphoma
|
1995
|
0.84
|
|
42
|
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
|
Bone Marrow Transplant
|
2005
|
0.82
|
|
43
|
Double-intensive therapy in high-risk multiple myeloma.
|
Blood
|
1992
|
0.81
|
|
44
|
CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.
|
J Clin Pathol
|
1995
|
0.81
|
|
45
|
Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.
|
J Clin Immunol
|
1993
|
0.81
|
|
46
|
Thalidomide in patients with advanced multiple myeloma.
|
Hematol J
|
2000
|
0.80
|
|
47
|
Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis.
|
Am J Med
|
1996
|
0.80
|
|
48
|
Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant.
|
Cancer Genet Cytogenet
|
1998
|
0.79
|
|
49
|
Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells.
|
Hum Gene Ther
|
1999
|
0.79
|
|
50
|
Isolated neurological relapse following stem cell transplantation in plasma cell leukemia: a report of two cases.
|
Leukemia
|
1999
|
0.79
|
|
51
|
Involvement of macrophages in lethal forms of graft-versus-host disease.
|
Lancet
|
1995
|
0.78
|
|
52
|
Early paternity and relapse after bone marrow transplantation.
|
Am J Hematol
|
1993
|
0.78
|
|
53
|
Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Français du Myélome (IFM)
|
Leukemia
|
1999
|
0.78
|
|
54
|
Very low incidence of p53 antibodies in adult non-Hodgkin's lymphoma and multiple myeloma.
|
Br J Haematol
|
1998
|
0.78
|
|
55
|
Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.
|
Leukemia
|
2012
|
0.77
|
|
56
|
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
|
J Clin Oncol
|
1997
|
0.77
|
|
57
|
Pseudomembranous conjunctivitis following bone marrow transplantation: immunopathological and ultrastructural study of one case.
|
Hum Pathol
|
1996
|
0.77
|
|
58
|
[Thalidomide: mechanisms of action and new insights in hematology].
|
Rev Med Interne
|
2005
|
0.77
|
|
59
|
Significance of circulating plasma cells in multiple myeloma.
|
Leuk Lymphoma
|
1994
|
0.77
|
|
60
|
Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.
|
Leukemia
|
2005
|
0.77
|
|
61
|
Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine.
|
J Clin Oncol
|
1989
|
0.77
|
|
62
|
Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells.
|
Br J Haematol
|
1995
|
0.76
|
|
63
|
Acute flare-up of conjunctival graft-versus-host disease with eosinophil infiltration in a patient with chronic graft-versus-host disease.
|
Leuk Lymphoma
|
2002
|
0.76
|
|
64
|
Cytomegalovirus expression in minor salivary glands and chronic graft-versus-host disease.
|
Bone Marrow Transplant
|
1994
|
0.76
|
|
65
|
Image analysis in multiple myeloma at diagnosis. Correlation with cytogenetic study.
|
Cancer Genet Cytogenet
|
1994
|
0.76
|
|
66
|
Combined anti-fungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation.
|
Bone Marrow Transplant
|
1999
|
0.76
|
|
67
|
Evaluation of minimal residual disease by interphase FISH in multiple myeloma: does complete remission exist?
|
Leukemia
|
1999
|
0.76
|
|
68
|
Soluble CD16 (sCD16), a marker of malignancy in individuals with monoclonal gammopathy of undetermined significance (MGUS).
|
Br J Haematol
|
1996
|
0.76
|
|
69
|
Acute and definitive renal failure in progressive multiple myeloma treated with recombinant interferon alpha-2a: report of two patients.
|
Am J Hematol
|
1992
|
0.75
|
|
70
|
VIM3-ARA C: an effective salvage regimen in refractory or recurrent aggressive non Hodgkin's lymphoma. A report on 18 cases.
|
Hematol Oncol
|
1992
|
0.75
|
|
71
|
Allogeneic bone marrow transplantation in multiple myeloma using HLA-compatible sibling donors--an EBMT Registry Study.
|
Bone Marrow Transplant
|
1991
|
0.75
|
|
72
|
Sequential high dose intravenous immunoglobulin for demyelinating neuropathy associated with monoclonal IgM gammapathy.
|
Eur J Med
|
1992
|
0.75
|
|
73
|
[Granulocytic sarcoma. Apropos of a case].
|
Ann Radiol (Paris)
|
1991
|
0.75
|
|
74
|
Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells.
|
Leukemia
|
1998
|
0.75
|
|
75
|
Two cases of t(1;16)(p11;p11) in multiple myeloma: confirmation by chromosome painting.
|
Cancer Genet Cytogenet
|
1994
|
0.75
|
|
76
|
Should all CMV infections after bone marrow transplantation be treated?
|
Bone Marrow Transplant
|
1991
|
0.75
|
|
77
|
[Acute lymphoblastic leukemia, Burkitt-cell type, after Hodgkin's disease. Study of 2 cases].
|
Nouv Rev Fr Hematol
|
1987
|
0.75
|
|
78
|
Induction of apoptosis by all-trans retinoic acid in the human myeloma cell line RPMI 8226 and negative regulation of some of its typical morphological features by dexamethasone.
|
Cell Death Differ
|
1999
|
0.75
|
|
79
|
Unusual recurrence of chronic myelogenous leukemia following bone marrow transplantation.
|
Bone Marrow Transplant
|
1991
|
0.75
|
|
80
|
Involvement of peripheral blood cells in multiple myeloma: chromosome changes are the rule within circulating plasma cells but not within B lymphocytes.
|
Leukemia
|
1997
|
0.75
|
|
81
|
Therapy related myelodysplastic syndrome and leukemia with no "unfavourable" cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases.
|
Leuk Lymphoma
|
1991
|
0.75
|
|
82
|
[Endobronchial plasmacytoma disclosing dysglobulinemia].
|
Rev Pneumol Clin
|
1993
|
0.75
|
|
83
|
[Correlation between the serum level of soluble CD16 and the staging of myeloma: study of 214 serums].
|
Rev Med Interne
|
1993
|
0.75
|
|
84
|
[Congenital asplenia, a differential diagnosis of essential thrombocythemia].
|
Presse Med
|
1993
|
0.75
|
|
85
|
[Mediastinal adenopathies and myeloma].
|
Rev Med Interne
|
1992
|
0.75
|
|
86
|
[Bone marrow monosomy 7 in children].
|
Arch Fr Pediatr
|
1988
|
0.75
|
|
87
|
[Malignant lymphoma of the testicles].
|
Rev Med Interne
|
1994
|
0.75
|
|
88
|
[Cutaneous manifestations of light chain deposition disease (Randall's syndrome)].
|
Ann Dermatol Venereol
|
1992
|
0.75
|
|
89
|
Soluble CD16 in plasma cell dyscrasias.
|
Leuk Lymphoma
|
1999
|
0.75
|
|
90
|
[Amyloidosis AL of the breast in an ileal carcinoid tumor].
|
Ann Pathol
|
1997
|
0.75
|
|
91
|
[Evaluation of primary amyloidosis using scintigraphy with the serum amyloid P component: from diagnosis to prognosis].
|
Rev Med Interne
|
1993
|
0.75
|
|
92
|
Acute monocytic leukemia with (8;22)(p11;q13) translocation. Involvement of 8p11 as in classical t(8;16)(p11;p13).
|
Cancer Genet Cytogenet
|
1992
|
0.75
|
|
93
|
[Myeloma with intrathoracic tumor expression].
|
Rev Mal Respir
|
1995
|
0.75
|